GURU.Markets stock price, segment price, and overall market index valuation
The company's share price 23andMe Holding Co.
TRxADE is a B2B platform for the pharmaceutical market, creating a transparent online marketplace. Its share price reflects its efforts to digitize drug procurement for independent pharmacies and compete with large distributors by offering them better prices and terms.
Share prices of companies in the market segment - Medanalysis
23andMe Holding Co. is a leading consumer genetics company offering DNA tests to determine ancestry and health risks. We've categorized it as a "Medical Analysis" company. The chart below shows how the market views the personalized medicine and genetic data sector.
Broad Market Index - GURU.Markets
23andMe is a pioneer in consumer genetics, providing genetic testing services to determine ancestry and health risks. As a leader, the company is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with 23andMe's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ME - Daily change in the company's share price 23andMe Holding Co.
The daily price change of 23andMe Holding Co. reflects volatility at the intersection of genetic testing and biotechnology. The metric demonstrates sensitivity to consumer demand for tests and advances in drug development.
Daily change in the price of a set of shares in a market segment - Medanalysis
23andMe is a pioneer in consumer genetics, offering ancestry and disease predisposition testing. This sector has faced challenges in commercialization. The chart below shows the volatility in this niche, reflecting high expectations and harsh market reality.
Daily change in the price of a broad market stock, index - GURU.Markets
23andMe is a pioneer in consumer genetic testing. The company's stock reflects both people's interest in their ancestry and health, as well as the long-term risks and prospects of its pharmaceutical division. This unique model creates its own volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization 23andMe Holding Co.
23andMe Holding Co.'s year-over-year performance is a story of its complex transformation. Its 12-month market cap reflects declining demand for its genetic testing and its expensive, yet unproductive, strategy of using its data for drug development. Its valuation reflects the market's deep skepticism of its business model.
Annual dynamics of market capitalization of the market segment - Medanalysis
23andMe, a pioneer in consumer genetic testing, is transforming itself by leveraging its massive database for drug development. This chart shows how the market is evaluating this complex but potentially disruptive strategy and its path to profitability in the healthcare sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
23andMe, a pioneer in consumer genetic testing, aims to leverage its vast data sets for drug development. Its year-over-year market capitalization reflects the complex transition from selling tests to building a pharmaceutical business.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization 23andMe Holding Co.
23andMe is a pioneer in consumer genetic testing. Its monthly performance reflects declining demand for its tests and its efforts to transition to a drug development model based on its genetic data. News from its R&D pipeline is becoming increasingly important.
Monthly dynamics of market capitalization of the market segment - Medanalysis
This chart reflects the dynamics of the consumer genetics sector. For 23andMe, a pioneer in this field, it's the backdrop. Its movements reflect the decline in demand for its tests and its complex transition to a model of drug development based on its genetic data.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
23andMe is a pioneer in consumer genetics, offering tests for ancestry and disease predisposition. The company is also exploring how to use its data for drug development. A full market chart helps assess how investors weigh the risks and potential of this unique, yet currently unprofitable, business model.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization 23andMe Holding Co.
The weekly performance of 23andMe, a pioneer in consumer genetic testing, reflects the complex journey from data collection to drug development. Its stock price is responding to news from its therapeutics division and the broader challenges of the DNA testing business model.
Weekly dynamics of market capitalization of the market segment - Medanalysis
23andMe, known for its genetic testing, is also involved in drug development. This dual model makes it unique. The chart allows you to compare its weekly performance with the sector and understand what influences it more: consumer trends in DNA testing or expectations for its biotech developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
23andMe is a well-known but risky genetic testing company. Shares of such innovative companies often react sharply to overall investor risk appetite. Use this chart to see if 23andMe is amplifying broader market fluctuations, or if news about its research and business model is creating its own trend.
Market capitalization of the company, segment and market as a whole
ME - Market capitalization of the company 23andMe Holding Co.
23andMe's market capitalization is a dramatic tale of the rise and fall of a genetics SPAC. The chart reflects the initial excitement about the potential of using data to create drugs. Its subsequent collapse is a narrative of slowing growth in the core testing business and the realization that the path from data to drugs is long, expensive, and uncertain.
ME - Share of the company's market capitalization 23andMe Holding Co. within the market segment - Medanalysis
23andMe is a pioneer and one of the most recognizable brands in the consumer genetics market. Its share of the segment's market capitalization reflects both its brand strength and growing competition. The chart demonstrates how the market views its leadership and ability to maintain its position in this innovative industry.
Market capitalization of the market segment - Medanalysis
23andMe is one of the first and most well-known companies in the field of consumer genetics. The chart below shows the overall market capitalization of the medical diagnostics sector. Its dynamics reflect both the growing interest in personalized medicine and the challenges associated with monetizing genetic data.
Market capitalization of all companies included in a broad market index - GURU.Markets
23andMe is a pioneer in consumer genetic testing. The company's market cap reflects a bet that our DNA data will become the foundation for personalized medicine. Its volatile performance on the overall chart reflects how the market is trying to assess the enormous, yet risky, potential of the genomic revolution.
Book value capitalization of the company, segment and market as a whole
ME - Book value capitalization of the company 23andMe Holding Co.
23andMe's balance sheet consists of its genetic analysis labs, equipment, and, most importantly, its massive DNA database, a valuable asset for drug development. Its book value reflects the underlying materiality of this unique bioinformatics company. How has this asset changed? The chart below tells its complex story.
ME - Share of the company's book capitalization 23andMe Holding Co. within the market segment - Medanalysis
23andMe, a leader in consumer genetics, uses massive, highly automated labs for DNA analysis. The chart shows the share of these unique and technologically advanced tangible assets in the sector, reflecting the physical foundation on which its genome sequencing business is built.
Market segment balance sheet capitalization - Medanalysis
23andMe, a genetic testing company, is a capital-intensive business. This requires the ownership of large, automated laboratories. The BCap_Seg chart for the medical equipment sector shows that leadership in diagnostics requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
23andMe's balance sheet isn't comprised of clinics, but rather one of the world's largest databases of genetic information and cutting-edge laboratories for its analysis. The company's assets are this unique information resource and technology. The chart shows how this "DNA bank," crucial for the future of medicine, compares in terms of assets today.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - 23andMe Holding Co.
23andMe's book value, comprised of its labs and offices, is negligible compared to its main asset—its massive genetic database. Its market capitalization is a bet on monetizing this data. The MvsBCap_Co chart here is an indicator of investors' faith in turning DNA information into real profit.
Market to book capitalization ratio in a market segment - Medanalysis
23andMe Holding Co. is known for its genetic testing, but its primary value to investors is its massive database for drug development. The chart clearly demonstrates that its market valuation significantly exceeds the value of its laboratories, reflecting its belief in future revenue from partnerships with pharmaceutical companies rather than from current test sales.
Market to book capitalization ratio for the market as a whole
For 23andMe, a genetic testing company, its core value lies not in its labs, but in its vast database and technology. It's a classic example of an intangible asset-based business, where the market valuation can be a multiple of its book value. The chart shows how large this premium is compared to the market average.
Debts of the company, segment and market as a whole
ME - Company debts 23andMe Holding Co.
23andMe, which combines consumer genetics with drug development, is using equity to fund its ambitious therapeutics division. Debt allows it to invest in long-term, expensive research based on its unique database. This chart illustrates how the company is funding its transformation into a fully-fledged biopharmaceutical company.
Market segment debts - Medanalysis
23andMe, known for its genetic testing, is transforming its business by leveraging its massive database for drug development. This strategy requires massive investments in R&D. This chart shows how the company is funding this ambitious transition—either through equity or by raising long-term debt to fund future discoveries.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio 23andMe Holding Co.
23andMe, known for its genetic testing, also develops drugs based on the data it collects. This requires significant investment in R&D. This chart shows how the company leverages its ambitious and expensive research, allowing us to assess its financial risk in developing new drugs.
Market segment debt to market segment book capitalization - Medanalysis
23andMe, a pioneer in consumer genetic testing, also uses its massive database for drug development. This dual business requires massive investments in R&D and marketing. The chart shows the overall debt load of the biotech sector, illustrating the financial environment under which 23andMe is attempting to monetize its unique assets.
Debt to book value of all companies in the market
23andMe Holding Co., a pioneer in consumer genetics, requires significant investment in research, data processing, and marketing. This chart, showing the overall market debt load, provides interesting context. It allows us to assess how a company at the intersection of technology and healthcare is funding its growth and managing capital.
P/E of the company, segment and market as a whole
P/E - 23andMe Holding Co.
23andMe Holding Co. is a pioneer in consumer genetic testing and data analysis. This chart shows the price-to-earnings ratio, but for 23andMe, it's less important than the potential of its biopharmaceutical division. Investors base their valuation on the company's ability to leverage its vast database to develop new drugs.
P/E of the market segment - Medanalysis
This chart shows the average valuation for companies in the consumer genetics and biotech sectors, providing context for 23andMe. It reflects high but volatile investor expectations. Comparisons with these valuations help understand how the market values 23andMe's unique dual business model (genetic testing and drug development) compared to other players.
P/E of the market as a whole
23andMe, a pioneer in consumer genetics, is attempting to transform its business into a fully-fledged pharmaceutical company using its unique data. Its valuation reflects this complex and risky transformation. It is entirely unrelated to the general economic cycles shown in this chart, but hinges on its ability to turn genetic data into approved drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company 23andMe Holding Co.
This chart for 23andMe Holding Co., known for its genetic testing, reflects market expectations for the future monetization of its massive database. It demonstrates analysts' confidence in the company's ability to use genetic information to develop drugs and partner with pharmaceutical giants, which drives its future profits.
%20P%2FE%2023andMe%20Holding%20Co.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-23andMe-Holding-Co.&v=1772659401218 "Chart of the company's future (projected) P/E 23andMe Holding Co.")
Future (projected) P/E of the market segment - Medanalysis
23andMe Holding Co. provides direct-to-consumer genetic testing services, providing information on ancestry and disease predisposition. The company also uses its database for drug development. The chart shows forecasts for the sector, allowing one to assess the market's confidence in 23andMe's ability to monetize its unique data in the pharmaceutical industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772659401220 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
23andMe Holding Co. is a pioneer in consumer genetic testing. The company also uses its data for drug development. Its valuation is a bet on the future of personalized medicine. This chart shows how much the market is willing to pay for long-term and ambitious projects at the intersection of technology and healthcare.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772659401223 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit 23andMe Holding Co.
23andMe Holding Co. is known for its consumer genetic tests that provide information about ancestry and health. The company's profits depend on test sales and monetization of its vast genetic database through partnerships with pharmaceutical companies. This chart illustrates the challenging path to profitability in the consumer genetics industry.
Profit of companies in the market segment - Medanalysis
23andMe opened the world of genetics to millions, enabling them to learn about their ancestry and health. This chart, showing profitability in the health analytics sector, highlights the challenges of their business model. After an initial surge in interest in DNA testing, the company's key goal became converting its massive database into sustainable revenue through research and personalized services.
Overall market profit
23andMe Holding Co. is a pioneer in consumer genetics, offering ancestry and disease predisposition testing. Demand for its services is driven by people's interest in their health and their discretionary spending. Overall revenue growth, driven by rising corporate profits, allows more people to spend money on such innovative products.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company 23andMe Holding Co.
23andMe Holding Co. is known for its consumer genetic testing, but its long-term strategy is to use its collected database for drug development. This chart reflects a complex analyst forecast, taking into account both test sales and speculative confidence in the potential breakthroughs of its therapeutics division.
%20profit%20of%20the%20company%2023andMe%20Holding%20Co.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-23andMe-Holding-Co.&v=1772659401270 "Graph of future (projected) profit of the company 23andMe Holding Co.")
Future (predicted) profit of companies in the market segment - Medanalysis
23andMe Holding Co. is a pioneer in consumer genetic testing and uses collected data for drug development. The company's business model is unique, combining services and biotechnology. This biotech chart reflects the market's overall belief in the potential of genetics and personalized medicine, which is key to 23andMe's long-term ambitions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772659401271 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
23andMe, a consumer genetics company, offers services that are not essential. Therefore, its business is sensitive to discretionary spending. This graph, showing economic profit expectations, is an indicator of consumers' willingness to spend money on understanding their health and ancestry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772659401276 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - 23andMe Holding Co.
23andMe is a pioneer in consumer genetic testing and research. Given the company's long history of operating at a loss, this chart is crucial. It shows the premium investors are paying for its revenue, betting on the long-term potential to monetize its massive genetic database for drug development.
P/S market segment - Medanalysis
23andMe Holding Co. is a pioneer in personal genetics, offering DNA tests to consumers and developing drugs based on its data. The company's revenue is diversified across testing and research. This chart shows the average valuation in the sector, helping to assess investor confidence in its unique model that combines data and pharmaceuticals.
P/S of the market as a whole
23andMe is a pioneer in consumer genetics, offering ancestry and disease predisposition testing. The company also uses its massive database for drug development. This chart, showing average market revenue estimates, helps us understand the premium investors are paying for its unique business model that combines services, data, and biotechnology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company 23andMe Holding Co.
23andMe is a pioneer in consumer genetics, offering tests for ancestry and disease predisposition. The company is also building a massive database for drug development. This chart reflects investor expectations not so much for current test sales as for the future potential of its therapeutics division and partnerships.
%20P%2FS%2023andMe%20Holding%20Co.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-23andMe-Holding-Co.&v=1772659401294 "The graph of the company's future (projected) P/S 23andMe Holding Co.")
Future (projected) P/S of the market segment - Medanalysis
23andMe Holding Co. is a pioneer in consumer genetics, offering DNA tests that provide information about ancestry and health. The company also uses its data for drug research and development. This chart shows the average future sales estimate in the health analytics sector, providing insight into how the market views 23andMe's unique business model.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772659401310 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
23andMe Holding Co. is a pioneer in consumer genetics, offering ancestry and disease predisposition testing. The optimism expressed in this chart is largely fueled by the growth of personalized medicine. 23andMe's success in monetizing genetic data for research demonstrates the potential of this emerging market at the intersection of technology and healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772659401323 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales 23andMe Holding Co.
This chart shows the revenue of 23andMe, a pioneer in consumer genetic testing. Revenue is generated from sales of DNA tests and subscriptions to premium health reports. The trend demonstrates consumer interest in personalized genetics, as well as the potential for monetizing its vast database for drug development.
Sales of companies in the market segment - Medanalysis
23andMe Holding Co. is a pioneer in consumer genetics, offering tests for ancestry and disease predisposition. This chart reflects the growth of the personalized diagnostics market. The company has not only created this niche but is also using the collected data for drug development, thereby expanding the boundaries of the entire sector from simple testing to therapeutics.
Overall market sales
23andMe offers genetic testing services directly to consumers. It's a discretionary purchase, and demand for it is growing with income. This total revenue chart reflects consumer confidence and people's willingness to spend money on non-essential health and self-knowledge services.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company 23andMe Holding Co.
23andMe is a pioneer in consumer genetics, offering tests for ancestry and disease predisposition. Future revenue depends on test sales and the success of drug development based on its vast genetic database. The chart reflects expectations for both businesses.
%20sales%20of%20the%20company%2023andMe%20Holding%20Co.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-23andMe-Holding-Co.&v=1772659401348 "Schedule of future (projected) sales of the company 23andMe Holding Co.")
Future (projected) sales of companies in the market segment - Medanalysis
23andMe is a pioneer in the direct-to-consumer genetics market, offering customers information about their ancestry and disease predispositions. The company also uses its massive database for drug development. This graph shows the forecast for the entire personalized medicine and genetic testing industry, which 23andMe helped create.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772659401361 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
23andMe is a leader in consumer genetics, offering DNA testing for ancestry and health. The company's products are discretionary purchases, with demand growing alongside incomes. This chart, reflecting overall consumer spending forecasts, serves as an indicator of people's willingness to spend money on self-knowledge and health.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772659401362 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality 23andMe Holding Co.
23andMe, a pioneer in consumer genetics, has a dual business model: selling DNA tests and using the collected data for drug development. The company's profitability is a complex balance between marketing spend on customer acquisition and long-term investments in R&D. This chart illustrates the challenge of turning genetic data into sustainable profit.
Market segment marginality - Medanalysis
23andMe is a pioneer in consumer genetics, offering DNA testing and analytics for health and ancestry. The company's business model is dual: selling tests and monetizing anonymized genetic data through R&D. This chart reflects the financial results of this unique strategy. A comparison with the industry demonstrates how successfully the company balances these two approaches.
Market marginality as a whole
23andMe is a pioneer in consumer genetics, offering ancestry and disease predisposition tests. They are now also developing drugs based on their data. This overall profitability curve is of little significance to them. Their success depends on growing interest in genetics and their ability to translate their unique database into new therapeutics.
Employees in the company, segment and market as a whole
Number of employees in the company 23andMe Holding Co.
23andMe is a pioneer in consumer genetics. Its staff is a unique combination of scientists working with a massive genetic database for drug discovery and specialists supporting its popular DNA tests. This chart shows investments in both its consumer products and pharmaceutical research.
Share of the company's employees 23andMe Holding Co. within the market segment - Medanalysis
23andMe is a pioneer in consumer genetics, providing millions of people with access to their DNA. This chart shows the company's talent pool in this niche. Behind each genetic report is a large team of scientists, researchers, and engineers who transform the data into personalized insights about health and ancestry.
Number of employees in the market segment - Medanalysis
23andMe Holding Co. is a pioneer in consumer genetics, offering DNA testing services to determine ancestry and health risks. This chart illustrates employment trends in the personalized medicine and genetic testing sector. The growth in the number of geneticists and data scientists reflects people's growing interest in their health and ancestry at the genetic level.
Number of employees in the market as a whole
23andMe Holding Co. offers genetic testing, which is a discretionary purchase. Consumer financial well-being, as illustrated by this employment graph, plays a key role. When people are confident in their income, they are more likely to spend money on health and self-knowledge services, expanding the company's market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company 23andMe Holding Co. (ME)
23andMe is a consumer genetics company. Its business is based not so much on physical tests as on a massive database and research. The chart shows the market value that investors attribute to each employee. At research-intensive companies like 23andMe, this metric reflects the value of intellectual property and the R&D potential generated by a relatively small team of scientists and analysts.
%20of%20the%20company%2023andMe%20Holding%20Co.%20(ME)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-23andMe-Holding-Co.-ME&v=1772659401391 "Chart of market capitalization per employee (in thousands of dollars) of the company 23andMe Holding Co. (ME)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
23andMe is a pioneer in consumer genetics, offering both ancestry tests and health reports. The company's core value lies in its massive database of genetic information, which can be used for research. This chart shows how the market values this unique information asset, generated by millions of customers.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772659401394 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
23andMe Holding Co. is a pioneer in consumer genetics and a data-driven drug developer. The chart illustrates the valuation of its unique business model. The high market capitalization per employee reflects the immense value of its unique genetic database, which is an asset for drug development.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772659401420 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company 23andMe Holding Co. (ME)
23andMe is a pioneer in consumer DNA testing. The company built its business on selling genetic reports, but its core value is its massive database. This chart reflects the company's transition to a new model: it now uses this data for drug development. Revenue per employee is the balance between revenue from testing and the enormous R&D costs of pharmaceuticals.
%20Chart%2023andMe%20Holding%20Co.%20(ME)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-23andMe-Holding-Co.-ME&v=1772659401441 "Company Profit Per Employee (in thousands of dollars) Chart 23andMe Holding Co. (ME)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
23andMe is a company known for its consumer DNA testing. Its business model is hybrid: it sells tests and uses the collected genetic data for drug development. This metric (currently a loss per employee) reflects the company's massive investment in R&D, which is not yet covered by revenue from test sales.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772659401447 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
23andMe is a company known for its B2C genetic testing. Their business model is dual: selling tests (low margins) and using the data for pharmaceutical R&D (high potential). This chart shows how profitable (or unprofitable) this hybrid model is. The loss per employee reflects the enormous R&D costs the company hopes to recoup through future drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772659401473 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee 23andMe Holding Co. (ME)
23andMe is a pioneer in consumer genetic testing. This chart illustrates the scalability of its business model. The growth in revenue per employee demonstrates the high degree of automation in its lab processes and the company's ability to monetize its vast array of genetic data through partnerships with pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-23andMe-Holding-Co.-ME&v=1772659401495 "Sales chart per company employee 23andMe Holding Co. (ME)")
Sales per employee in the market segment - Medanalysis
23andMe has a dual business model: selling genetic tests to the public and using this database for pharmaceutical R&D. This chart shows the total revenue per employee across both activities (from lab technician to data scientist). This allows us to assess how productive their hybrid "tests + data" model is compared to other companies in the segment.
Sales per employee for the market as a whole
23andMe has a hybrid business model: (1) selling genetic tests directly to consumers (DTC) and (2) developing drugs based on the collected database. Test sales are scalable, with a high degree of laboratory automation. The R&D division, by contrast, requires a large staff of scientists. This chart shows how successfully the company monetizes its tests.
Short shares by company, segment and market as a whole
Shares shorted by company 23andMe Holding Co. (ME)
23andMe is known for its DNA ancestry tests, but its business model has shifted toward unprofitable drug development. This chart shows bearish sentiment. Investors are betting that consumer interest in genetic testing has waned and that its pharmaceutical ambitions will fail, burning through its remaining capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-23andMe-Holding-Co.-ME&v=1772659401555 "Short Shares Chart for the Company 23andMe Holding Co. (ME)")
Shares shorted by market segment - Medanalysis
23andMe Holding Co. is known for its direct-to-consumer (DTC) genetic testing services, providing customers with ancestry and health information. The company also uses its database for drug development. This chart reflects the aggregate downward bias across the medical diagnostics and research sector. It highlights the extent to which the market is skeptical of business models in this space or anticipates stricter data regulation.
Shares shorted by the overall market
23andMe (ME) is a genetic testing company. It's largely a lifestyle medicine company. When this fear indicator rises, investors anticipate a recession. They fear that consumers will primarily abandon expensive, "optional" medical tests paid for out of pocket.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator 23andMe Holding Co. (ME)
This chart for 23andMe is a barometer for consumer genetics. "Overheating" (above 70) was due to SPAC hype and the belief in data monetization through pharmaceuticals. "Oversold" (below 30) was caused by falling demand for tests, high cash burn, and the recent data breach completely destroyed confidence, sending the oscillator to rock bottom.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-23andMe-Holding-Co.-ME&v=1772659401603 "RSI 14 indicator chart for the company's stock 23andMe Holding Co. (ME)")
RSI 14 Market Segment - Medanalysis
23andMe (ME) is a pioneer in the world of consumer genetics. They sell DNA tests and also use their massive database for drug development. This chart measures the pulse of the Medical Analysis sector. It helps investors understand whether ME's performance reflects their sophisticated business model or whether the entire industry is overheated by genomics hype.
RSI 14 for the overall market
For 23andMe, this chart is an indicator of spending on "hobbies" and R&D. In a euphoric mood, consumers are eager to spend on "optional" DNA tests. In a panic, these spendings are cut. At the same time, panicked investors are fleeing the loss-making R&D division (its pharmaceutical business), which is burning through cash.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ME (23andMe Holding Co.)
23andMe (ME) is a leading consumer genetics company. It sells DNA tests (for ancestry and health) and uses this data for R&D (drug development). This chart shows the average 12-month price target from analysts, reflecting their view on this complex, dual-track business model.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ME-23andMe-Holding-Co.&v=1772659401682 "A chart showing analyst consensus forecasts for the expected stock price. ME (23andMe Holding Co.)")
The difference between the consensus estimate and the actual stock price ME (23andMe Holding Co.)
23andMe (ME) is the "DNA revolution." The company began as a direct-to-consumer (DTC) provider of genetic testing and now uses its massive database to develop its own drugs. This chart measures the gap between the current price and the consensus target price. It shows whether experts believe they can monetize this unique "bio-library."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ME-23andMe-Holding-Co.&v=1772659401689 "A chart showing the difference between the consensus forecast and the actual stock price. ME (23andMe Holding Co.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
23andMe (ME) is a company of two halves: a renowned consumer DNA testing service ("ancestry"), now used as a data engine for its own drug R&D pipeline. This chart reflects the collective opinion of the *entire* medical analysis/biotech sector. It shows whether experts believe in this "data-to-drug" model.
Analysts' consensus forecast for the overall market share price
23andMe (ME) is a company known for its consumer DNA testing. But its primary focus is using this massive database to discover new drugs. This chart shows the company's overall risk appetite. For 23andMe, whose business is a hybrid of wellness and speculative biotech, overall optimism (a rising chart) is critical to its funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index 23andMe Holding Co.
23andMe is a direct-to-consumer library of your DNA. Their gimmick is two businesses: 1. (Their cash cow) direct-to-consumer sales of genetic tests (Who are your ancestors?), and 2. (Their Holy Grail) R&D: using this gigantic DNA database (with customers' permission) to discover new drugs (in partnership with GSK). This chart is a summary indicator of their (complex) model.
AKIMA Market Segment Index - Medanalysis
23andMe (ME) is a mass-market DNA analytics company. They started with DNA tests for ancestry and now use this massive database to develop new drugs. They're a hybrid of B2C and biotech. This chart compares their composite index to the sector, showing how their DNA database outperforms the competition.
The AKIM Index for the overall market
23andMe is a pioneer in consumer genetics. It provides DNA testing and uses data for drug development. This chart, reflecting the market average, is a backdrop. It helps assess how 23andMe, which is struggling to monetize its database, compares to overall macroeconomic trends.
